BGJ398 (NVP-BGJ398)

Catalog No.S2183

BGJ398 (NVP-BGJ398) Chemical Structure

Molecular Weight(MW): 560.48

BGJ398 (NVP-BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM in cell-free assays, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • Activation of FGFR2 and MAPK by FGFR2-AHCYL1 and its suppression by FGFR inhibitors. Lysates from NIN3T3 cells expressing FGFR2-AHCYL1 or EZR-ROS1 (control) treated with vehicle (DMSO), 0.2 and 1 µM BGJ398, and 0.2 and 1 µM PD173074 were immunoblotted with the relevant antibodies. β-actin was used as a loading control.

    Hepatology 2014 59(4), 1427-34. BGJ398 (NVP-BGJ398) purchased from Selleck.

    Anchorage-independent growth of NIN3T3 cells expressing FGFR2 fusions and its suppression by FGFR inhibitors (BGJ: BGJ398 and PD: PD173074). The percentage (+/- s.d.) of colonies formed in the presence of FGFR2 inhibitors (0.2 礛) and by KD mutants with respect to those formed by DMSO-treated cells are plotted at the bottom. The NIH3T3 clone expressing EZR-ROS1 was used as a negative control for FGFR inhibitors. *P<0.05.

    Hepatology 2014 59(4), 1427-34. BGJ398 (NVP-BGJ398) purchased from Selleck.

  • we used a FGFR inhibitor (BGJ398) and a MEK inhibitor (PD98059) to confirm that the inhibition of FGF pathway was directly related to the fibroblast-like conversion, and same morphologic change and increased expression of Vim and COL I was observed

    Oncogene, 2017, 36(27):3831-3841. BGJ398 (NVP-BGJ398) purchased from Selleck.

    BGJ398 inhibits signaling in cell lines with activating FGFR alterations. Immunoblot demonstrates the expression of total/pFGFRs and total/pFRS2 in DMSO and BGJ398 in treated cell lines (A) DMS114. B, RT112. Lysates were prepared from cells exposed to BGJ398 (at the indicated concentrations) for 24 hours and immunoblots performed with the respective antibodies. Representative data are shown from three experimental replicates. Bar graphs display densitometric analysis of protein bands using GAPDH as a control. BGJ398 treatment results in decreased levels of pFGFR1/pFGFR3 and pFRS2/total FRS2, respectively.

    Mol Cancer Ther, 2017, 16(4):614-624. BGJ398 (NVP-BGJ398) purchased from Selleck.

  • BGJ39 distinctly inhibited the inductive effect of FGF2. Just as the results of western blot, BGJ39 not only reversed the down-expression of E-cadherin, but also weakened the expression of BSP and OPN. However, combination of both TGF- β1 and FGF2 containing BGJ39 distinctly improved the expression of fibronectin and periostin. β-actin was used as an internal control for equal protein loading. * P < 0.05, ** P < 0.01.

    J Cell Physiol 2014 229(11), 1647-59. BGJ398 (NVP-BGJ398) purchased from Selleck.

Purity & Quality Control

Choose Selective FGFR Inhibitors

Biological Activity

Description BGJ398 (NVP-BGJ398) is a potent and selective FGFR inhibitor for FGFR1/2/3 with IC50 of 0.9 nM/1.4 nM/1 nM in cell-free assays, >40-fold selective for FGFR versus FGFR4 and VEGFR2, and little activity to Abl, Fyn, Kit, Lck, Lyn and Yes. Phase 2.
FGFR1 [1]
(Cell-free assay)
FGFR3 [1]
(Cell-free assay)
FGFR2 [1]
(Cell-free assay)
FGFR3 (K650E) [1]
(Cell-free assay)
FGFR4 [1]
(Cell-free assay)
0.9 nM 1.0 nM 1.4 nM 4.9 nM 60 nM
In vitro

BGJ398 also prevents VEGFR2 with low potency. The IC50 of BGJ398 for inhibiting VEGFR2 is 0.18 μM. BGJ398 suppresses other kinases including ABL, FYN, KIT, LCK, LYN and YES with IC50 of 2.3 μM, 1.9 μM, 0.75 μM, 2.5 μM, 0.3 μM and 1.1 μM, respectively. At the cellular level, BGJ398 inhibits the proliferation of the FGFR1-, FGFR2-Q, and FGFR3-dependent BaF3 cells with IC50 of 2.9 μM, 2.0 μM and 2 μM, respectively. BGJ398 interferes with autophosphorylation on specific tyrosine residues including FGFR-WT, FGFR2-WT, FGFR3-K650E, FGFR3-S249C and FGFR4-WT with IC50 of 4.6 nM, 4.9 nM, 5 nM, 5 nM and 168 nM, respectively. BGJ398 suppresses proliferation of the cancer cells with wild-type (WT) FGFR3 overexpression such as RT112, RT4, SW780 and JMSU1 with IC50 of 5 nM, 30 nM, 32 nM and 15 nM, respectively. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCC MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3S4b|EuOjVyMDDuUS=> NVjQXFBbPDhiaB?= NVe2SVdxyqCLQ{WwQUAzOzV74pEJco0> MmPyNlU3QDh5NEO=
HCT116 NG\HRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTZc3dLPDhiaB?= NX3z[4FJUUN3ME2zJO69VQ>? MlvBNlQ2ODN3M{i=
HKH2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUn0[YpYPDhiaB?= NFnnZXlKSzVyPUSg{txO MkDINlQ2ODN3M{i=
RKO MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUXRfFVtPDhiaB?= MnXKTWM2OD1zLkKg{txO MkPPNlQ2ODN3M{i=
LS174T M2\kWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED0TXk1QCCq NHf4WodKSzVyPUSg{txO M4izflI1PTB|NUO4
HCD9 MlvqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVqwMlUuPSEQvF2= MlTROFgwPzJiaB?= MmP2SG1UVw>? MYrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHl? NWnER493OjRzM{W4NVY>
HCT116 MlPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWm3cHNrOC53LUWg{txO NV[yb4VPPDhxN{KgbC=> MWPEUXNQ NX;mOFQ3\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5 M{GxNFI1OTN3OEG2
SNU-C1 M37h[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorhNE42NTVizszN M{nad|Q5Nzd{IHi= MXjEUXNQ NIfZUmlvdyCnZn\lZ5Q> M1PHN|I1OTN3OEG2
MFE280 M2LKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fZd2lEPTB;Mj62N{DDuSByLkiyJO69VQ>? NIDE[|kzOzR2M{iwOS=>
AN3CA MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVj2WZN4UUN3ME2xMlAxKMLzIECuNlAh|ryP MUeyN|Q1OzhyNR?=
MFE296 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\MdGpZUUN3ME2yMlg3KMLzIECuNlAh|ryP M2jr[|I{PDR|OEC1
SPAC1S MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4C4O2lEPTB;Mz6xPUDDuSByLkmzJO69VQ>? MVeyN|Q1OzhyNR?=
RL952 MlLSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXL2Wo1OUUN3ME2zMlQyKMLzIECuNlMh|ryP M1Xn[FI{PDR|OEC1
EN1 M{\Ec2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHNdYE4UUN3ME20Mlc2KMLzIECuOlIh|ryP NHqwUXczOzR2M{iwOS=>
SNGII NH\uUIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknPTWM2OD12LkK5JOKyKDBwNUig{txO M3zreFI{PDR|OEC1
HEC1A M325dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDQUpBKSzVyPUGwMlAxKMLzIEGuNFAh|ryP Mn3WNlM1PDN6MEW=
SNGM Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvRTWM2OD13LkCwJOKyKDBwNEGg{txO NGHK[GYzOzR2M{iwOS=>
USPC2 M{jvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmL3TWM2OD15LkCwJOKyKDBwMkGg{txO NUnCVpl[OjN2NEO4NFU>
MFE319 M4\CXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTVwM{egxtEhOC5yMzFOwG0> M{LyUVI{PDR|OEC1
EFE184 Ml3sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2XISWlEPTB;OD6wOEDDuSByLk[5JO69VQ>? MUGyN|Q1OzhyNR?=
ECC1 NVzyTGJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXTJR|UxRTZwN{SgxtEhOC53OTFOwG0> NH3hbGQzOzR2M{iwOS=>
HEC1B NYrFUHRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDTc5hKSzVyPU[uOFUhyrFiMD62O{DPxE1? MYCyN|Q1OzhyNR?=
USPC1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2zTWM2OD13Lke1JOKyKDBwNUCg{txO MnHZNlM1PDN6MEW=

... Click to View More Cell Line Experimental Data

In vivo In this orthotopic xenograft bladder cancer model, BGJ398 induces tumor growth inhibition and stasis after oral administration for 12 consecutive days at the doses of 10 and 30 mg/kg, respectively. Interestingly, the animals that received BGJ398 exhibits either no body weight loss (10 mg/kg) or 10% body weight gain (30 mg/kg), a further indication of efficacy. RT112 tumor-bearing and female Rowett rats receive a single oral administration of the monophosphate salt of BGJ398 at the doses of 4.25 and 8.51 mg/kg. BGJ398 significantly decreases the levels of pFRS2 and pMAPK in a dose-dependent manner. BGJ398 inhibits significantly bFGF-stimulated angiogenesis in a dose-dependent manner. However, BGJ398 does not impair VEGF-induced blood vessel formation. [1]


Kinase Assay: [1]
+ Expand

Radiometric kinase assay:

The enzymatic kinase activity is assessed by measuring the phosphorylation of a synthetic substrate by the purified GST-fusion FGFR3-K650E kinase domain, in the presence of radiolabeled ATP. Enzyme activities are measured by mixing 10 μL of a 3-fold concentrated BGJ398 solution or control with 10 μL of the corresponding substrate mixture (peptidic substrate, ATP and [γ33P]ATP). The reactions are initiated by addition of 10 μL of a 3-fold concentrated solution of the enzyme in assay buffer. The final concentrations of the assay components are as following: 10 ng of GST-FGFR3-K650E, 20 mM Tris-HCl, pH 7.5, 3 mM MnCl2, 3 mM MgCl2, 1 mM DTT, 250 μg/mL PEG 20000, 2 μg/mL poly(EY) 4:1, 1% DMSO and 0.5 μM ATP (γ-[33P]-ATP 0.1 μCi). The assay is carried out according to the filter binding (FB) method in 96-well plates at room temperature for 10 minutes in a final volume of 30 μL including BGJ398. The enzymatic reactions are stopped by the addition of 20 μL of 125 mM EDTA, and the incorporation of 33P into the polypeptidic substrates is quantified as following: 30 μL of the stopped reaction mixture are transferred onto Immobilon-PVDF membranes previously soaked for 5 minutes with methanol, rinsed with water, soaked for 5 min with 0.5% H3PO4, and mounted on vacuum manifold with disconnected vacuum source. After spotting, vacuum is connected, and each well rinsed with 0.5% H3PO4 (200 μL). Free membranes are removed and ished four times on a shaker with 1% H3PO4 and once with ethanol. Membranes are dried and overlaid with addition of 10 μL/well of a scintillation fluid. The plates are eventually sealed and counted in a microplate scintillation counter. IC50 values are calculated by linear regression analysis of the percentage inhibition of the BGJ398.
Cell Research:[1]
+ Expand
  • Cell lines: Murine BaF3 cell lines
  • Concentrations: 0 μM-0.1 μM
  • Incubation Time: 48 hours
  • Method: Murine BaF3 cell lines, whose proliferation and survival has been rendered IL-3-independent by stable transduction with tyrosine kinases activated either by mutation or fusion with a dimerizing partner, are cultured in RPMI-1640 media supplemented with 10% FBS, 4.5 g/L glucose, 1.5 g/L sodium bicarbonate, and Pen/Strep. Cells are passaged twice weekly. BGJ398-mediated inhibition of BaF3 cell proliferation and viability is assessed using a Luciferase bioluminescent assay. Exponentially growing BaF3 or BaF3 Tel-TK cells are seeded into 384-well plates (4250 cells/well) at 50 μL/well using a μFill liquid dispenser in fresh medium. BGJ398 is serially diluted in DMSO and arrayed in a polypropylene 384-well plate. Then 50 nL of BGJ398 are transferred into the plates containing the cells by using the pintool transfer device, and the plates incubated at 37 °C (5% CO2) for 48 hours. Then 25 μL of Bright-Glo are added, and luminescence is quantified using an Analyst-GT. Custom curve-fitting software is used to produce a logistic fit of percent cell viability as a function of the logarithm of inhibitor concentration. The IC50 value is determined as the concentration of BGJ398 needed to reduce cell viability to 50% of a DMSO control.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Athymic nude-nu mice bearing parental RT112 cell line
  • Formulation: PEG300/D5W (2:1, v/v)
  • Dosages: 10 mg/kg/qd and 30 mg/kg/qd
  • Administration: Oral administration
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 1 mg/mL warmed (1.78 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
For best results, use promptly after mixing.

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 560.48


CAS No. 872511-34-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03510455 Not yet recruiting Tumor-Induced Osteomalacia National Institute of Dental and Craniofacial Research (NIDCR)|National Institutes of Health Clinical Center (CC) November 20 2018 Phase 2
NCT02706691 Recruiting FGFR Gene Amplification|FGFR1 Gene Amplification|FGFR2 Gene Amplification|FGFR2 Gene Mutation|FGFR3 Gene Mutation|Head and Neck Squamous Cell Carcinoma|Human Papillomavirus Infection|Recurrent Head and Neck Carcinoma|Recurrent Nasopharynx Carcinoma|Recurrent Oropharyngeal Squamous Cell Carcinoma University of Chicago|Novartis June 1 2018 Phase 2
NCT02657486 Recruiting Bladder Cancer|Non-Muscle-Invasive Urothelial Carcinoma Memorial Sloan Kettering Cancer Center January 2016 Not Applicable
NCT02312804 Withdrawn Cancer of Cervix|Tumors The University of Texas Health Science Center at San Antonio January 2015 Phase 1
NCT02257541 Active not recruiting Advanced Gastrointestinal Stromal Tumor (GIST) Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute|M.D. Anderson Cancer Center|University of Pittsburgh October 2 2014 Phase 1|Phase 2
NCT02160041 Completed Solid Tumor|Hematologic Malignancies Novartis Pharmaceuticals|Novartis July 24 2014 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    If you have any suggestions about the formulation of this compound for a direct oral gavage administration?

  • Answer:

    BGJ398 (S2183) can be dissolved in 30% PEG400/0.5% Tween80/5% Propylene glycol at 30 mg/ml as a suspension.

FGFR Signaling Pathway Map

FGFR Inhibitors with Unique Features

Related FGFR Products4

Tags: buy BGJ398 (NVP-BGJ398) | BGJ398 (NVP-BGJ398) supplier | purchase BGJ398 (NVP-BGJ398) | BGJ398 (NVP-BGJ398) cost | BGJ398 (NVP-BGJ398) manufacturer | order BGJ398 (NVP-BGJ398) | BGJ398 (NVP-BGJ398) distributor
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID